The value of serum survivin level in early diagnosis of cancer
Autor: | Yildiz Okuturlar, Nilgun Isiksacan, Turkan Ozturk Topcu, Meral Gunaldi, Hakan Kocoglu, Mehmet Karabulut, Omur Gunaldi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Colorectal cancer medicine.medical_treatment survivin Malignancy lcsh:RC254-282 Inhibitor of Apoptosis Proteins 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors Prostate Neoplasms Internal medicine Survivin Biomarkers Tumor medicine Humans Radiology Nuclear Medicine and imaging Early Detection of Cancer Aged Cancer Neovascularization Pathologic business.industry diagnostic marker General Medicine Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Healthy Volunteers Radiation therapy 030104 developmental biology medicine.anatomical_structure risk indicator 030220 oncology & carcinogenesis Female prognosis Ovarian cancer business malignancy |
Zdroj: | Journal of Cancer Research and Therapeutics, Vol 14, Iss 3, Pp 570-573 (2018) |
ISSN: | 1998-4138 0973-1482 |
Popis: | Objective: Survivin is one of the apoptosis inhibitor proteins, and it plays a key role in tumor angiogenesis and cancer progression. This study was conducted to investigate the serum level of survivin to determine its diagnostic value in cancer patients. Materials and Methods: Blood samples were taken from cancer patients (n = 67) prior to surgery or chemo/radiotherapy and age-matched healthy volunteers (n = 23). The serum levels of survivin were analyzed by enzyme-linked immunosorbent assays. The difference in serum levels between patients and control was evaluated by using statistical methods. Correlation between the serum levels of survivin and clinicopathological features of cancer patients were also evaluated. Results: The diagnoses of patients were breast cancer (49.3%), colon cancer (25.4%), ovarian cancer (14.9%), and other cancers (10.4%). Serum survivin levels were significantly higher in cancer patients than healthy subjects (196.23 pg/ml vs. 117.73 pg/ml, respectively, P = 0.019). No significant relations were found between serum survivin level and demographic characteristics of cancer. The optimal cut-off value of serum survivin was determined at >120.8 pg/ml, and its serum levels above this cut-off value were associated with 4.198 times increased risk of cancer. Conclusion: Our study results may suggest that high serum survivin levels can show 4 times increased risk of cancer in a subject with a high suspicion of cancer. Furthermore, survivin level was not influenced with demographic characteristics of breast, gastric, colorectal, prostate, ovarian cancer, and glioblastome multiforme. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.